Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Intronic SNP - rs9288953 Of Suppressor Molecule Btla Confers Susceptibility To B-Cell Chronic Lymphocytic Leukemia

Irena Frydecka, II, Anna Partyka, MsC, Anna Tomkiewicz, MsC, Edyta Pawlak-Adamska, PhD, Olga Grzybowska–Izydorczyk, MD, Ewa Lech–Maranda, MD, Agnieszka Bojarska–Junak, PhD, Iwona Hus, Tadeusz Robak, Jacek M. Rolinski, Lidia Karabon, PhD

Blood (2013) 122 (21): 5286.

https://doi.org/10.1182/blood.V122.21.5286.5286

Published: 2013

Journal Articles

Vaccination of B-CLL Patients with Autologous Dendritic Cells Results in Immunological and Clinical Responses.

Iwona Hus, MD, PhD, Michael Schmitt, MD, PhD, Jacek Tabarkiewicz, MD, PhD, Sebastian Radej, MD, Agnieszka Bojarska-Junak, PhD, Kamila Wojas, PhD, Anita Schmitt, MD, PhD, Krzysztof Giannopoulos, MD, PhD, Anna Dmoszynska, MD, PhD, Jacek Rolinski, MD, PhD

Blood (2007) 110 (11): 2052.

https://doi.org/10.1182/blood.V110.11.2052.2052

Published: 2007

Journal Articles

Thalidomide Alone and in Combination with Fludarabine Exerts Distinct Molecular and Antileukemic Effects in B-Cell Chronic Lymphocytic Leukemia.

Krzysztof Giannopoulos, MD, PhD, Anna Dmoszynska, MD, PhD, Malgorzata Kowal, MD, PhD, Ewa Wasik-Szczepanek, MD, PhD, Paulina Wlasiuk, MA, Agnieszka Bojarska-Junak, PhD, Jacek Rolinski, MD, PhD, Stephan Stilgenbauer, MD, PhD, Lars Bullinger, MD, PhD

Blood (2007) 110 (11): 3124.

https://doi.org/10.1182/blood.V110.11.3124.3124

Published: 2007

Journal Articles

Clinical Efficacy and Safety of Combined Thalidomide and Fludarabine Therapy in B-Cell Chronic Lymphocytic Leukemia Patients.

Anna Dmoszynska, Krzysztof Giannopoulos, MD, PhD, Malgorzata Kowal, MD, PhD, Monika Podhorecka, MD, PhD, Paulina Wlasiuk, MSc, Agnieszka Bojarska-Junak, PhD, Wioletta Trzesniewska, MD, Jacek Rolinski

Blood (2006) 108 (11): 4975.

https://doi.org/10.1182/blood.V108.11.4975.4975

Published: 2006

Journal Articles

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) Is a Potential Target for Immunotherapy of Patients with B-Cell Chronic Lymphocytic Leukemia.

Krzysztof Giannopoulos, MD, Iwona Hus, PhD, Li Li, MD, Agnieszka Bojarska-Junak, PhD, Jochen Greiner, MD, Jacek Rolinski, PhD, Anna Dmoszynska, PhD, Hartmut Doehner, MD, Michael Schmitt, MD

Blood (2005) 106 (11): 53.

https://doi.org/10.1182/blood.V106.11.53.53

Published: 2005

NARROW

Intronic SNP - rs9288953 Of Suppressor Molecule Btla Confers Susceptibility To B-Cell Chronic Lymphocytic Leukemia

Vaccination of B-CLL Patients with Autologous Dendritic Cells Results in Immunological and Clinical Responses.

Thalidomide Alone and in Combination with Fludarabine Exerts Distinct Molecular and Antileukemic Effects in B-Cell Chronic Lymphocytic Leukemia.

Clinical Efficacy and Safety of Combined Thalidomide and Fludarabine Therapy in B-Cell Chronic Lymphocytic Leukemia Patients.

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) Is a Potential Target for Immunotherapy of Patients with B-Cell Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Intronic SNP - rs9288953 Of Suppressor Molecule Btla Confers Susceptibility To B-Cell Chronic Lymphocytic Leukemia

Vaccination of B-CLL Patients with Autologous Dendritic Cells Results in Immunological and Clinical Responses.

Thalidomide Alone and in Combination with Fludarabine Exerts Distinct Molecular and Antileukemic Effects in B-Cell Chronic Lymphocytic Leukemia.

Clinical Efficacy and Safety of Combined Thalidomide and Fludarabine Therapy in B-Cell Chronic Lymphocytic Leukemia Patients.

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) Is a Potential Target for Immunotherapy of Patients with B-Cell Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only